Journal article

Treating Obstructive Sleep Apnea with Hypoglossal Nerve Stimulation

Peter R Eastwood, Maree Barnes, Jennifer H Walsh, Kathleen J Maddison, Geoffrey Hee, Alan R Schwartz, Philip L Smith, Atul Malhotra, R Douglas McEvoy, John R Wheatley, Fergal J O'Donoghue, Peter D Rochford, Tom Churchward, Matthew C Campbell, Carsten E Paime, Sam Robinson, George S Goding, Danny J Eckert, Amy S Jordan, Peter G Catcheside Show all

Sleep | OXFORD UNIV PRESS INC | Published : 2011


BACKGROUND: Reduced upper airway muscle activity during sleep is fundamental to obstructive sleep apnea (OSA) pathogenesis. Hypoglossal nerve stimulation (HGNS) counteracts this problem, with potential to reduce OSA severity. STUDY OBJECTIVES: To examine safety and efficacy of a novel HGNS system (HGNS, Apnex Medical, Inc.) in treating OSA. PARTICIPANTS: Twenty-one patients, 67% male, age (mean ± SD) 53.6 ± 9.2 years, with moderate to severe OSA and unable to tolerate continuous positive airway pressure (CPAP). DESIGN: Each participant underwent surgical implantation of the HGNS system in a prospective single-arm interventional trial. OSA severity was defined by apnea-hypopnea index (AHI) du..

View full abstract


Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by NHMRC

Awarded by American Heart Association


Funding Acknowledgements

Dr. Eastwood is funded by a National Health and Medical Research Council of Australia (NHMRC) Senior Research Fellowship No. 513704. Dr. Kezirian was supported by a career development award from the National Center for Research Resources (NCRR) of the National Institutes of Health and a Triological Society Research Career Development Award of the American Laryngological, Rhinological, and Otological Society. Dr. Eckert is supported by an Overseas Based Biomedical (CJ Martin) Fellowship from the NHMRC (510392) and the American Heart Association (10SDG3510018). The authors acknowledge the assistance of Mr. Chris Mullin from Apnex Medical Inc, with the statistical analyses. The authors note with sadness the untimely death of their collaborator Dr Sam Robinson and dedicate this manuscript to him.This study was funded by Apnex Medical and Phillips Respironics provided medical equipment. Dr. Antic has received honorarium from ResMed and AtheroGenics and is a co-investigator on the partially industry supported SAVE study. Drs. Eastwood, Hillman, Schwartz, and Kezirian serve as on the medical advisory board and are consultants for Apnex Medical, Dr. Hillman has received honorarium and medical equipment from ResMed Inc. Dr. Eckert has received research support from Sepracor Pharmaceuticals, Dr. Schwartz also serves as a consultant or on the advisory board of Cardiac Concepts, Sleep Science, Soya Pharmaceutical and has received medical equipment from ResMed. Dr. Kezirian also serves as a consultant or is on the advisory board for ArthroCare, Medtronic, Pavad Medical, and Re Vent Medical. Dr. Malhotra has received consulting and/or research income from NIH, AHA, Apnex, Apnicure, Philips, Ethicon, Medtronic, Pfizer, Merck, SGS, SHC, Cephalon, Sepracor, and Galleon. Drs. Eckert, Smith, Hee, and Jordan serve as consultants for Apnex Medical. Drs. Eastwood, Jordan, Barnes, and Maddison have received research equipment from ResMed Inc. Dr. McEvoy has received research grants from Respironics Foundation, ResMed, and Fisher and Paykel. Dr. Rochford has received research funding from Compumedics Australia Limited. Dr. Barnes has also received salary support for a research assistant from Bird (Pyt) Ltd. and research support from Fisher & Paykel, Actelion Pharmaceuticals, Boehringer-Ingelheim, Glaxo Smith Kline, Novartis, Hunter Immunology, and Sanofi Aventis, Dr. Wheatley has received research support from Actelion Pharmaceuticals, Boehringer Ingelheim, and Glaxo Smith Kline. Dr. Tyler has received research support from Actelion Pharmaceuticals. Dr. Worsnop has received speaking honorarium from Medinah International, The University of Melbourne, Glaxo Smith Kline, AstraZeneca, Pfizer, Nycomed, Novartis, Actelion Pharmaceuticals, and Boehringer Ingelheim.